Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
Open Access
- 16 August 2019
- journal article
- research article
- Published by Springer Nature in Diagnostic Pathology
- Vol. 14 (1) , 1-6
Abstract
Urothelial carcinoma in situ (CIS) in the bladder can be difficult to diagnose due to factors including procedural artifact, minimal tissue sampled, therapy-related changes, and various CIS growth patterns. Prior data has demonstrated an increase in alpha-methylacyl-CoA-racemase (AMACR) in urothelial CIS, but there is no information on its utility for diagnosing difficult cases. The aim of this investigation was to assess the expression of AMACR that was ordered on equivocal bladder cases during clinical practice. Transurethral resections of the bladder in which AMACR and CK20 were performed during diagnostic workup were identified and cases with a final diagnosis of CIS (n = 22) or non-neoplastic urothelium (n = 30) were selected. Additionally, cases in which a diagnosis of CIS was rendered without IHC (n = 20) were selected and tested for AMACR expression. Sensitivity of AMACR for CIS diagnosed with IHC during clinical practice was 73% and specificity was 97%, while CK20 was 95% sensitive and 80% specific. Sensitivity of AMACR in CIS diagnosed without IHC was 100%. In all groups, AMACR had inconsistent intensity, compared to CK20 which had consistent, strong intensity. AMACR was usually positive in urothelial CIS and negative in non-neoplastic urothelium. However, it is important to note that AMACR was less sensitive in difficult cases, while CK20 was more sensitive with more consistent, strong staining compared to AMACR.Keywords
This publication has 20 references indexed in Scilit:
- Utility of a Triple Antibody Cocktail Intraurothelial Neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-Methylacyl-CoA Racemase (AMACR) in the Distinction of Urothelial Carcinoma In Situ (CIS) and Reactive Urothelial AtypiaAmerican Journal of Surgical Pathology, 2013
- Utility of Cytokeratin 5/6, Cytokeratin 20, and p16 in the Diagnosis of Reactive Urothelial Atypia and Noninvasive Component of Urothelial NeoplasiaApplied Immunohistochemistry & Molecular Morphology, 2012
- Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic ReviewEuropean Urology, 2011
- Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette–Guérin immunotherapy on the outcomeScandinavian Journal of Urology and Nephrology, 2011
- Clinical Outcomes of Primary Bladder Carcinoma In Situ in a Contemporary SeriesJournal of Urology, 2010
- Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancerVirchows Archiv, 2008
- Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progressionVirchows Archiv, 2005
- Utility of cytokeratin 20 and Ki‐67 as markers of urothelial dysplasiaPathology International, 2005
- Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial DysplasiaLaboratory Investigation, 2003
- Discriminatory Immunohistochemical Staining of Urothelial Carcinoma in Situ and Non-neoplastic UrotheliumAmerican Journal of Surgical Pathology, 2001